Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others. As of 25 May 2026, CORONA REMEDIES LIMITED share price is ₹1,690.00. The stock opened at ₹1,718.00, compared to its previous close of ₹1,684.60. During today's trading session, CORONA REMEDIES LIMITED share price moved in the range of ₹1,681.00 to ₹1,719.90, with an average price of ₹1,700.45 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,681.00 and a high of ₹1,719.90. On the performance front, CORONA REMEDIES LIMITED share price has increased by 17.12% over the last six months and is up 17.12% on a year-on-year basis.
The market capitalization of CORONA REMEDIES LIMITED is ₹10,289 Crs, with a P/E ratio of 55.6 and a dividend yield of 0.00%.